"Cafepharma Daily New Headlines" - 5 new articles

On April 24, Astellas Pharma Inc. revealed that XTANDI enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC) treatment in the European Union (EU).

     

The research center will focus on developing solutions for manufacturing biopharmaceuticals, including antibodies, recombinant proteins, and viral vectors. It is expected to open in 2027 with 550 employees.

     

On Thursday, European drugmakers Sanofi and AstraZeneca announced several pipeline cuts in their respective first-quarter 2024 financial results, including assets to treat Sjögren’s syndrome and cardiovascular disease.

     

William Blair analyst Andrew Brackmann said Labcorp is being aggressive in its M&A strategy, after announcing last month it would buy several of Bioreference Health’s testing businesses.

     

Walgreens is expanding its specialty pharmacy offerings, including gene and cell therapy services, the company said April 25.

The rebranded business, Walgreens Specialty Pharmacy, includes an 18,000-square-foot facility in Pittsburgh, four central specialty pharmacies and nearly 300 community specialty pharmacies, according to a news release. The company also has 1,500 specialty-trained pharmacists, 5,000 patient advocacy support team members and 240 limited distribution drugs.